Archived documents

The below archived documents are available on our archived website:

  • Experimental and Unproven Treatments – Sets out the circumstances in which NHS England may wish to fund a treatment or intervention which is either considered experimental or not to be of proven effectiveness
  • Prioritisation framework. NHS England has developed a framework for how it makes relative prioritisation decisions for new investments in specialised services. The framework was developed through stakeholder engagement and public consultation.
    • Specialised Services report
    • Annex E – Public Consultation period engagement report
    • NHS England response publication document
    • PPVAG Response – Prioritisation Consultation April 2015
    • CPAG Response Investing in Specialised Services Consultation

    In April 2016 NHS England held a second public consultation called Developing a Method to Assist Investment Decisions in Specialised Services. This consultation set out a method that it was proposed would be used by the Clinical Priorities Advisory Group when making recommendations on investment decisions for 2016/17. NHS England’s response to consultation (June 2016) confirmed that the method would be adopted for 2016/17 and it described how learning from that year’s commissioning round would inform the development of the method for future years, including through further stakeholder engagement where appropriate. Published documents relating to this consultation are: Consultation guide, NHS England response to consultation.

  • Collaborative commissioning guidance. Developing a more collaborative approach to the commissioning of specialised services sets out the vision and next steps for how Clinical Commissioning Groups and NHS England can work together to develop better outcomes and better experience of care through a more collaborative approach to the commissioning of specialised services for 2015/16 and beyond.  The guidance document is supported by a suite of tools and resources to help with implementation.
  • Standard operating procedure for funding requests for Clinically Critically Urgent treatment outside established policy: Guidance outlining how NHS England will manage funding requests for designated specialised treatments that are considered by the referring clinician as potentially clinically critically urgent.
  • Defining the boundaries between NHS and private healthcare This policy defines the boundaries between privately funded treatment and entitlement to NHS funding, under a range of circumstances.
  • Choice – Policy on choices for elective referrals for which NHS England is responsible.
  • Patients changing responsible commissioner – States NHS England’s policy on when it will accept responsibility for existing funding commitments made by patients’ previous commissioning bodies e.g. Primary Care Trust or Clinical Commissioning Group
  • Implementation and Funding of NICE Guidance – Sets out how NHS England will respond to the implementation and related funding of new guidance from the National Institute of Clinical Excellence (NICE)
  • In-Year Service Developments – States NHS England’s position on requests for the recurrent funding of new services.
  • On-going Treatment Following a NHS CB Funded Trial – Sets out NHS England’s policy on access to treatment following the completion of a trial which it has explicitly funded
  • On-going Treatment Following Non-Commercially Funded Clinical Trials – Sets out NHS England’s policy on access to treatment following the completion a non-commercially funded trial
  • On-going access to treatment following a trial of treatment – Sets out NHS England’s policy with regard to the funding of a patient’s treatment at the end of a ‘trial of treatment’ which it does not normally commission.
  • On-going Access to Treatment Following Industry Sponsored Clinical Trials or Funding – Sets out NHS England’s policy on access to treatment following the completion of industry sponsored clinical trials or funding